Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.
Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. · 1999
Read Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. by Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. (1999) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2362742.txt.
Introduction
Cuschieri and colleagues reported long-term results of a UK trial on stomach cancer surgery in 1999. The question was how much lymph tissue to remove. A D1 operation takes only the glands next to the stomach, while the Japanese-style D2 takes glands further out as well. Japanese reports claimed far better survival with D2, but without randomised proof.
The trial randomised 400 patients after checks showed their cancer might be curable. With a median follow-up of 6.5 years, five-year survival was 35% after D1 and 33% after D2, a difference of minus 2 points that could easily be chance. Deaths from stomach cancer and cancer returns also matched closely. Older age, male sex, later stage, and removal of the spleen or pancreas each predicted worse survival. The authors concluded D2 offers no advantage as performed here.
Catalog record
| CREATOR | Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. |
|---|---|
| YEAR | 1999 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial By A Cuschieri, S Weeden, J Fielding, J Bancewicz, J Craven, V Joypaul, M Sydes, P Fayers Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6690243 ABSTRACT Controversy still exists on the optimal surgical resection for potentially curable gastric cancer. Much better long-term survival has been reported in retrospective/non-randomized studies with D 2 resections that involve a radical extended regional lymphadenectomy than with the standard D 1 resections. In this paper we report the long-term survival of patients entered into a randomized study, with follow-up to death or 3 years in 96% of patients and a median follow-up of 6.5 years. In this prospective trial D 1 resection (removal of regional perigastric nodes) was compared with D 2 resection (extended lymphadenectomy to include level 1 and 2 regional nodes). Central randomization followed a staging laparotomy. Out of 737 patients with histologically proven gastric adenocarcinoma registered, 337 patients were ineligible by staging laparotomy because of advanced disease and 400 were randomized. The 5-year survival rates were 35% for D 1 resection and 33% for D 2 resection (difference –2%, 95% CI = –12%–8%). There was no difference in the overall 5-year survival between the two arms (HR = 1.10, 95% CI 0.87–1.39, where HR > 1 implies a survival benefit to D 1 surgery). Survival based on death from gastric cancer as the event was similar in the D 1 and D 2 groups (HR = 1.05, 95% CI 0.79–1.39) as was recurrence-free survival (HR = 1.03, 95% CI 0.82–1.29). In a multivariate analysis, clinical stages II and III, old age, male sex and removal of spleen and pancreas were independently associated with poor survival. These findings indicate that the classical Japanese D 2 resection offers no survival advantage over D 1 surgery. However, the possibility that D 2 resection without pancreatico-splenectomy may be better than standard D 1 resection cannot be dismissed by the results of this trial. © 1999 Cancer Research Campaign Carcinoma of the stomach remains a major cause of death in most Western countries. The only proven effective therapy is surgery, but overall 5-year survival rates remain low after resection. In 1981, the Japanese Society for Research in Gastric Cancer (JSRGC) standardized the gastric resections and the extent of regional lymphadenectomy in accordance with specific rules (updated over the years) based on the location of the tumour and the respective regional node drainage (Kajitani, 1981). Large retrospective series from Japan of radical gastrectomy with level-2 extended lymphadenectomy (D2 resections) have shown impres- sive 5-year survival rates, certainly much higher than experienced in the West (Mine et al, 1970; Miwa, 1979; Maruyama et al, 1987; Nakajima and Nishi, 1989). Some non-Japanese centres have also reported favourably on D2 resections (Smith et al, 1991; Jaehne et al, 1992; Siewert et al, 1993; Sue-Ling et al, 1993; Mendes et al, 1994). However, the benefit of D2 over conventional D1 resections (where only the perigastric nodes within 3.0 cm of the primary are removed) had not been tested prospectively until the launch of the Medical Research Council (MRC) Gastric Cancer Surgical Trial (ST01) in 1986. This was a randomized comparison of D1 versus D2 resections for potentially curable advanced gastric cancer. At the time the study was formulated, the Japanese rules dictated that pancreatico-splenectomy was an integral part of D2 resection for all tumours except antral cancers. For this reason en-bloc removal of these two organs with the stomach was specified by the MRC ST01 trial protocol for middle and upper third tumours in the D2 arm. In this paper, we report on the long-term outcome of these two surgical treatment arms. Preliminary results of ST01 (Cuschieri et al, 1996), and a similar Dutch trial (Bonenkamp et al, 1995), have shown that splenectomy and distal hemi-pancreatec- tomy are attended by a significant increase in post-operative morbidity and mortality. The influence of removal of these organs on long-term survival is addressed in this analysis. This is impor- tant as distal hemi-pancreatectomy is no longer considered an inte- gral part of D2 resections by Japanese surgeons, and some Western centres are practising spleen- and pancreas-preserving D2 resec- tions with apparent good results (Sue-Ling et al, 1993; Griffith, 1995), despite the reported splenic hilar lymph nodes involvement in 15-27% of gastric cancers (Fass and Schumpelick, 1989; Mendes et al, 1994; Mendes et al, 1995; Tsuburaya et al, 1995). PATIENTS AND METHODS The organization and preliminary results of the MRC ST01 trial are summarized briefly since they have been reported previously (Cuschieri et al, 1996). Patients enrolled in MRC ST01 were to have histologically proven, and potentially curable, gastric carci- noma. Patients were excluded if they were young (< 20 years), had Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial A Cuschieri1, S Weeden2, J Fielding3, J Bancewicz4, J Craven5, V Joypaul1, M Sydes2 and P Fayers2, for the Surgical Co-operative Group 1University Department of Surgery, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; 2Cancer Division MRC Clinical Trials Unit, Cambridge, UK; 3Queen Elizabeth Hospital, Birmingham, UK; 4University Department of Surgery, Hope Hospital, Salford, UK; 5Kingstown General Hospital, St Vincents, Jamaica Summary Controversy still exists on the optimal surgical resection for potentially curable gastric cancer. Much better long-term survival has been reported in retrospective/non-randomized studies with D2 resections that involve a radical extended regional lymphadenectomy than with the standard D1 resections. In this paper we report the long-term survival of patients entered into a randomized study, with follow-up to death or 3 years in 96% of patients and a median follow-up of 6.5 years. In this prospective trial D1 resection (removal of regional perigastric nodes) was compared with D2 resection (extended lymphadenectomy to include level 1 and 2 regional nodes). Central randomization followed a staging laparotomy. Out of 737 patients with histologically proven gastric adenocarcinoma registered, 337 patients were ineligible by staging laparotomy because of advanced disease and 400 were randomized. The 5-year survival rates were 35% for D1 resection and 33% for D2 resection (difference -2%, 95% CI = -12%-8%). There was no difference in the overall 5-year survival between the two arms (HR = 1.10, 95% CI 0.87-1.39, where HR > 1 implies a survival benefit to D1 surgery). Survival based on death from gastric cancer as the event was similar in the D1 and D2 groups (HR = 1.05, 95% CI 0.79-1.39) as was recurrence-free survival (HR = 1.03, 95% CI 0.82-1.29). In a multivariate analysis, clinical stages II and III, old age, male sex and removal of spleen and pancreas were independently associated with poor survival. These findings indicate that the classical Japanese D2 resection offers no survival advantage over D1 surgery. However, the possibility that D2 resection without pancreatico-splenectomy may be better than standard D1 resection cannot be dismissed by the results of this trial. Keywords: gastric cancer; D1 resection; D2 resection; long-term survival 1522 British Journal of Cancer (1999) 79(9/10), 1522-1530 (c) 1999 Cancer Research Campaign Article no. bjoc.1998.0243 Received 14 July 1998 Revised 20 October 1998 Accepted 5 November 1998 Correspondence to: A Cuschieri D1 and D2 resections